|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, in vitro transfection of polo-like kinase 1 (PLK1) siRNA by FA-PEG-modified liposomes exhibited strong cytotoxicity in KB cells, compared with PEG-modified liposomes; however, in in vivo therapy, intratumoral injection of PEG-modified PLK1 siRNA lipoplexes inhibited tumor growth of KB xenografts, as well as that of FA-PEG-modified PLK1 siRNA lipoplexes.
|
30991703 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To date, functions of PLK1 and MYC on tumor are mostly studied in separate researches, and studies on their mutual crosstalk are lacking.
|
31571905 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In-silico design and synthesis of N9-substituted β-Carbolines as PLK-1 inhibitors and their in-vitro/in-vivo tumor suppressing evaluation.
|
31015177 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of PLK1 by a PLK1-specific small molecule inhibitor was shown to restore G2/M checkpoint in vitro and to reduce tumor burden in vivo.
|
30246253 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, we show a synergistic combination between C-siPLK1-NP and radiation, which was confirmed in vivo in A549 flank tumors.
|
31563561 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This review summarizes the proposed mechanisms by which Plk1 can play as an oncogene or as a tumor suppressor, and extrapolates this information to clinical features.
|
30862113 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
While there is significant downregulation of tumor suppressor microRNA-34a (miR-34a), which targets many oncogenes related to proliferation, apoptosis, and invasion, high expression level of Polo-like kinase 1 (PLK1) is closely associated with short survival rates of pancreatic cancer patients.
|
30933478 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment with the PLK1 inhibitor volasertib (BI6727) significantly inhibited tumor growth in nude mice.
|
31281496 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We report the hydrophobically-tagged Plk1 PBD inhibitor Poloxin-2HT+, which selectively degrades the tumor target Plk1 and induces apoptosis in human tumor cells with higher potency than the hydrophobically-tagged inhibitor Poloxin-2HT.
|
30848278 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Genomic <i>MYC</i> alteration may serve as a biomarker for PLK inhibitor sensitivity, as Myc-driven tumors demonstrated pronounced responses.
|
30217967 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Based on immunohistochemistry findings, the PLK1 protein is expressed at higher levels in SCLC tumor samples than in normal lung tissue samples.
|
30118839 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LACP can enter tumor cells and release CP into the cytosol by laser-triggered thermo-effects of the AuNPs; the CP can enter nuclei by TAT guidance, enabling effective knock-outs of target gene (Plk-1) of tumor (melanoma) and inhibition of the tumor both in vitro and in vivo.
|
29282854 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Plk1 is upregulated in many tumor types including colorectal cancer (CRC) and portends a poor prognosis.
|
29402316 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Herein, we show that a combination of Plk1 inhibitor GSK461364A and BRD4 inhibitor JQ1 had a strong synergistic effect on castration-resistant prostate cancer (CRPC) cell lines, as well as in CRPC xenograft tumors.
|
29716963 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells.
|
29549256 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PLK1 inhibition significantly inhibited tumor growth.
|
30157470 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide-Hoechst Conjugate Suppresses Tumor Growth <i>In Vivo</i>.
|
29483218 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After performing single or multiplex gene editing with an efficiency up to 47.3% in vitro, we demonstrated that P-HNPs delivering Cas9 plasmid/sgRNA targeting the polo-like kinase 1 (Plk1) gene achieved 35% gene deletion in HeLa tumor tissue to reduce the Plk1 protein level by 66.7%, thereby suppressing the tumor growth by >71% and prolonging the animal survival rate to 60% within 60 days.
|
29686087 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
|
29437878 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Let-7b over-expression inhibited the development and growth of implanted HCC tumors in mice by decreasing PLK1 and Survivin expression in the tumors.
|
29913237 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, in vivo antitumor activity demonstrated that PHD/LR could efficiently accumulated into tumor tissue and silenced PLK1 expression to possess antitumor activity.
|
30498349 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, despite the therapeutic benefits of inhibiting Plk1 due to its essential role in tumor cell cycles, Plk1 overexpression has tumor-suppressive properties by perturbing mitotic progression and cytokinesis.
|
30069007 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
More importantly, in vivo by analyzing tumorigenesis in patient-derived tumor xenograft (PDTX) models, the inhibition of PLK1 activity by BI6727 significantly decreased the volume and weight of the tumors compared with control group (<i>P</i><0.01).
|
30288059 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We developed Poloxin-2HT by fusing an adamantyl tag to Poloxin-2, an inhibitor of the polo-box domain of the protein kinase Plk1, which is a target for tumor therapy.
|
30351497 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a result, the codelivery of PTX and PLK1 siRNA exerts a stronger combinational effect against tumor growth in MDR tumor models in vivo.
|
28152267 |
2017 |